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Peritoneal spread is one of major causes of mortality in colorectal
cancer patients. In the current investigation, the efficacy of radio-
immunotherapy (RIT) with i.p. administration of an anti-colorectal
cancer IgG1, 131I-A7, was compared to that with i.v. administration
in BALB/c female mice bearing peritoneal nodules of LS180 hu-
man colon cancer cells, at the same toxicity level. Distribution of
either i.p. or i.v. administered 131I-A7 and i.p. administered irrele-
vant 131I-HPMS-1 was assessed. Based on the results of toxicity
determination at increments of 2 MBq and estimated dosimetry,
an i.p. dose of 11 MBq and an i.v. dose of 9 MBq were chosen for
treatment. Mice were monitored for long-term survival: un-
treated mice (n=11), mice undergoing i.p. RIT with 131I-A7 (n=11),
mice undergoing i.v. RIT with 131I-A7 (n=11) and mice undergoing
non-specific i.p. RIT with 131I-HPMS-1 (n=5). Intraperitoneal injec-
tion of 131I-A7 produced faster and greater tumor accumulation
than i.v. injection: 34.2±16.5% of the injected dose per g (% ID/
g) and 11.1±3.6% ID/g at 2 h, respectively (P<0.0001). Conse-
quently, cumulative radioactivity in tumors was 1.73-fold higher
with i.p. injection. 131I-HPMS-1 did not show specific accumula-
tion. Non-specific RIT with 131I-HPMS-1 (mean survival, 26.0±2.5
days) did not affect the survival as compared to no treatment
(26.7±1.9 days). Intravenous RIT with 131I-A7 prolonged the sur-
vival of mice to 32.8±1.8 days (P<0.01). Intraperitoneal RIT with
131I-A7 improved the survival more significantly and attained cure
in 2 of 11 mice (P<0.05 vs. i.v. RIT). In conclusion, i.p. RIT is more
beneficial in treating peritoneal carcinomatosis of colon cancer
than i.v. RIT in a murine model. (Cancer Sci 2003; 94: 650–654) 
eritoneal spread is a sign of the terminal stage in colorectal
cancer, being one of major causes of mortality in patients.1–3)
Intraperitoneal chemotherapy in combination with cytoreduc-
tive surgery—peritonectomy—has been examined as a thera-
peutic option to prolong the survival of patients,1–3) but the
majority eventually dies of progressive disease.
Several reports have indicated the effectiveness of radioim-
munotherapy (RIT) employing radiolabeled monoclonal anti-
bodies (MAb) under conditions of minimal tumor burden in
cancer patients.4–10) One of the major obstacles to RIT with i.v.
injected MAb is inadequate targeting of MAb to tumors.11) Pre-
vious studies have indicated that greater accumulation in perito-
neal tumors can be achieved with i.p. injection of MAb than
with systemic injection.12–25) Furthermore, higher tumor-to-nor-
mal tissue uptake ratios are achievable with i.p. injection, re-
sulting in a favorable dosimetry, not only as regards the
radiation dose to tumors but also the toxicity profile.
Feasibility of i.p. RIT has been extensively investigated in
ovarian cancer patients because of the high incidence of perito-
neal dissemination of ovarian cancer12–20); indeed, prolonged
survival with RIT has been documented. However, the effec-
tiveness of i.p. RIT has not been fully validated for the treat-
ment of peritoneal carcinomatosis of colorectal cancer despite
reports demonstrating the dosimetric advantages of i.p. injec-
tion of MAb in peritoneal tumors.21–25) Therefore, we aimed to
compare the therapeutic efficacy of intraperitoneal RIT and i.v.
RIT performed at the same toxicity level in a mouse model of
human colon cancer.
Materials and Methods
Monoclonal antibodies. A7, an IgG1 murine MAb with κ-light
chain, was used in this investigation.26) It was purified from as-
cites of hybridoma-bearing mice by Protein A Sepharose col-
umn (Bio-Rad, Richmond, CA) chromatography. A7 MAb
recognizes a 45-kD surface glycoprotein of human colonic car-
cinomas. The antigen is modulated after binding with A7, and
the internalization of A7 occurs. A7 does not react with normal
gastric mucosa, erythrocytes, peripheral lymphocytes or ileal
mucosa, and shows weak reactivity with 10% of colon mucosa
specimens. An additional IgG1 recognizing placental alkaline
phosphatase, HPMS-1, was utilized as a class-matched irrele-
vant control MAb.27) Antibodies were radiolabeled with 131I by
the chloramine-T method, and subsequently purified on a PD10
column (Pharmacia LKB Biotechnology, Uppsala, Sweden).
The specific activity of purified 131I-A7 was 175–247 MBq/
mg. Immunoreactivity of purified 131I-A7 determined under an-
tigen excess conditions with LS180 human colon cancer cell
line (American Type Culture Collection, Rockville, MD) was
74–82%. The specific activity of 131I-HPMS-1 was 259 MBq/
mg. Antibodies were sterilized by filtration (Millex-GV, 0.22
mm; Millipore, Bedford, MA) prior to further experiments.
Peritoneal metastasis model. Animal studies were performed in
compliance with the regulations of our institution. LS180 cells
were grown in DMEM medium (Nissui Seiyaku, Tokyo), har-
vested with 0.1% trypsin, washed and subsequently suspended
in PBS at 1×108/ml. An aliquot of the cell suspension (0.1 ml)
was injected i.p. into Balb/c nu /nu mice (female, 20 g; NINOX
Labo Supply, Inc., Ishikawa). Peritoneal nodules reach several
mm in diameter by 10 days after cell inoculation.
Biodistribution of antibodies. Mice bearing peritoneal nodules
were injected either i.p. or i.v. with 111 kBq (3 µCi) of 131I-A7
10 days after inoculation of tumor cells. The animals were sac-
rificed 2 and 6 h and 1, 2 and 3 days later (n=3–5). Organs
were excised and weighed; subsequently, radioactivity of the
tissues was measured with a well-type γ-counter. In order to an-
alyze the relationship between metastasis size and 131I-MAb ac-
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Nodules were individually weighed and counted for radioactiv-
ity. The biodistribution of i.p. injected 131I-HPMS-1 was simi-
larly observed 1 and 2 days after injection as a negative control
(n=3), and the results were analyzed by means of the Mann-
Whitney test. The level of significance was set at 5%.
Determination of toxicity. Toxicity was determined for i.p. and
i.v. administration of 131I-A7 by assessing thrombocytopenia
and body weight loss after 131I-A7 administration at increments
of 2 MBq. A blood sample (5 µl) was obtained from a tail vein
of each mouse. Samples within a single group (n=3) were
pooled and diluted 1:100 in 1% ammonium oxalate for platelet
counts.
For the dosimetric assessment, cumulative radioactivity after
131I-A7 administration in 1 g of tissue (MBq×h/g) was obtained
by the trapezoid integration method using the biodistribution
data.
Radioimmunotherapy. The therapeutic experiment consisted of
four groups: non-treated mice (n=11), mice undergoing specific
RIT with i.p. injection of 131I-A7 (n=11), mice undergoing spe-
cific RIT with i.v. injection of 131I-A7 (n=11), and mice under-
going non-specific RIT with i.p. injection of an irrelevant 131I-
HPMS-1 (n=5). Administration doses were chosen based on
the results of toxicity determination. The dose of 131I-HPMS-1
was set at the same level as that of 131I-A7. MAbs were admin-
istered 10 days after inoculation of tumor cells. Animals were
monitored for survival. Results were analyzed by the Kaplan-
Meier method with the log rank test. The level of significance
was set at 5%.
Results
Intraperitoneal injection of 131I-A7 resulted in faster and
greater accumulation than i.v. injection: 34.2±16.5% ID/g and
11.1±3.6% ID/g at 2 h after injection, respectively (P<0.0001)
(Fig. 1, A and B). On the other hand, the i.v. route yielded peak
activity in tumors 1 day after injection (Fig. 1B). Radioactivity
level in tumors was similar in the two groups at late time
points. Accumulation in tumors increased with decreasing size
in both administration routes (Fig. 2). An irrelevant MAb,
Fig. 1. Biodistribution of i.p. injected 131I-A7 (A) and i.v. injected 131I-
A7 (B) in mice bearing peritoneal metastases (n=3–5). Accumulation of
an irrelevant 131I-HPMS-1 in metastases is also shown (A) (n=3). Values
of tumor accumulation are means±SD of all samples obtained in each
group. In general, 10–20 metastatic nodules of various sizes ranging
0.1–400 mg were measured for antibody accumulation in each mouse.
No significant differences were observed in the distribution of lesional
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Fig. 2. Size-effect of peritoneal metastatic nodules on accumulation
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Fig. 3. Change of platelet count induced by 131I-A7 administered ei-
ther i.p. or i.v.Kinuya et al. Cancer Sci | July 2003 | Vol. 94 | no. 7 | 651
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Toxicity of 131I-A7 administration was dose-dependent (Fig.
3 and Fig. 4). Because the body weight of mice receiving an i.v.
dose of 11 MBq was greatly decreased and recovery was poor,
the second highest dose, 9 MBq, was chosen for the i.v. dose in
therapeutic assessment. Based on the degrees of platelet depres-
sion and body weight loss, an i.p. dose of 11 MBq was deter-
mined to be equitoxic. According to these results, cumulative
radioactivity values in tissues were calculated for the adminis-
tration of i.v. 9 MBq and i.p. 11 MBq (Table 1). Cumulative ra-
dioactivity in normal tissues was nearly identical after i.v. 9
MBq and i.p. 11 MBq, validating the results of toxicity deter-
mination. At these administration doses, i.p. injection of 131I-A7
produced 1.73-fold higher cumulative radioactivity in perito-
neal tumors than i.v. administration, and therapeutic ratios rela-
tive to normal organs were significantly higher with i.p.
injection.
All mice with peritoneal metastases died by 33 days after cell
inoculation if no treatment was conducted (Fig. 5). Mean sur-
vival of non-treated mice was 26.7±1.9 days. Non-specific RIT
with an irrelevant 131I-HPMS-1 (mean survival, 26.0±2.5 days),
did not affect the survival as compared to no treatment. Intrave-
nous RIT with 131I-A7 prolonged the survival of animals to
32.8±1.8 days (P<0.01). Intraperitoneal RIT with 131I-A7 im-
proved the survival more significantly (P<0.05). Moreover, i.p.
RIT attained cure in 2 of 11 mice.
Discussion
RIT currently utilizes β emitters to treat cancer lesions. Clinical
RIT in patients with bulky solid tumors has shown only limited
success.11) On the other hand, recent investigations have indi-
cated the role of RIT in an adjuvant setting where small resid-
ual tumors are targeted by radiolabeled MAb,4–10) despite the
limitations of β emitters suggested by mathematical model
analyses.28) A factor influencing the effectiveness of RIT in
small tumors is the size-dependency of MAb accumulation in
tumors.29, 30) In the current investigation, we found that this situ-
ation is also true in targeting i.p. metastases of 0.1–400 mg.
One of the major reasons for therapeutic failure of clinical
RIT in solid tumors is an insufficient radiation dose to tu-
mors.11) To overcome this limitation, locoregional delivery of
labeled MAb has been proposed, especially in ovarian cancer
patients because of the high incidence of peritoneal dissemina-
tion of ovarian cancer.12–20) In colorectal cancer, the dosimetric
advantage of i.p. administration has been similarly acknowl-
edged21–25); however, the effectiveness of i.p. RIT relative to
i.v. RIT has not been validated so far. The current investigation
confirmed better therapeutic effects as well as more favora-
ble dosimetry of i.p. RIT as compared to i.v. RIT in a perito-
neal metastasis model.
Because of Michaelis-Menten kinetics in antibody-antigen
interactions,31) the higher MAb concentration in the peritoneal
cavity achieved by i.p. administration than i.v. administration is
beneficial. Slow absorption of large molecules such as MAbs
from the peritoneal cavity may maintain high concentration.32)
These factors cause rapid and intense localization of MAb in
peritoneal tumors, resulting in considerably higher therapeutic




























Fig. 4. Body weight loss induced by 131I-A7 administered either i.p. or
i.v.
Table 1. Cumulative radioactivity after i.p. or i.v. administration of 131I-A7
Cumulative radioactivity 
(MBq×h/g) Metastasis-to-normal tissue ratio
i.p. i.v. i.p. i.v. i.p./i.v.
Blood 61.3 70.4 1.75 0.88 1.98
Liver 17.6 18.8 6.09 3.29 1.85
Spleen 18.1 16.6 5.93 3.73 1.59
Kidney 15.6 13.2 6.86 4.70 1.46
Bone 7.2 7.0 14.80 8.83 1.68
Muscle 5.3 4.3 20.17 14.31 1.41
Intestine 11.1 8.3 9.62 7.45 1.29
Metastasis 107.0 62.0 — — —
i.p., intraperitoneal administration (11 MBq); i.v., intravenous administration (9 MBq);
i.p./i.v., ratio of metastasis-to-normal tissue ratio of i.p. administered 131I-A7 to that of
i.v. administered 131I-A7.
Time after cell inoculation (d)









Fig. 5. Survival of mice bearing peritoneal metastases. Radioimmuno-
therapy (RIT) was performed 10 days after cell inoculation. , non-
treated control; , non-specific RIT with an irrelevant 131I-HPMS-1 i.p.
injected; , i.v. RIT with 131I-A7; , i.p. RIT with 131I-A7. Doses of i.p.
RIT and i.v. RIT were 11 MBq and 9 MBq, respectively.652 Kinuya et al.
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suggests that RIT employing radionuclides with physical half
life shorter than 131I would deliver radiation to tumors more ef-
fectively.
Liver metastasis occurs more often than peritoneal spread in
colon cancer patients, and both types of metastases may simul-
taneously exist. We have previously demonstrated the effective-
ness of RIT in a liver metastasis model of colon cancer in
which radio-labeled A7 was administered systemically.33–35) In-
traperitoneal MAb administration reportedly produces a similar
degree of MAb accumulation in liver metastases as compared
to i.v. injection,36) so that i.p. RIT may work in treating liver
metastases as well as peritoneal lesions.
Previous studies demonstrated the improvement of therapeu-
tic outcomes with combination treatment of RIT and chemo-
therapy in comparison with monotherapy.37, 38) For instance,
specificity of 5-FU against cells in the S-phase of the cell cycle
suggests that 5-FU may act selectively against less radiosensi-
tive cells.39) Furthermore, chemotherapeutic drugs may act as a
radiosensitizer so that the interaction with RIT may not be a
simple additive effect, but rather a synergistic effect.39) This
combination therapy seems worth evaluating in a peritoneal
metastasis model.
In conclusion, i.p. administration of 131I-A7 affords an im-
provement in terms of absorbed radiation dose to colon cancer
metastases within the peritoneal cavity in a murine model, lead-
ing to longer survival in mice treated via the i.p. route in com-
parison with the i.v. route.
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